Smart Radiotherapy Biomaterials for Image-Guided In Situ Cancer Vaccination

Author:

Ainsworth Victoria12,Moreau Michele12ORCID,Guthier Romy23ORCID,Zegeye Ysaac34,Kozono David3,Swanson William5ORCID,Jandel Marian2,Oh Philmo6,Quon Harry1,Hobbs Robert F.1,Yasmin-Karim Sayeda37,Sajo Erno2ORCID,Ngwa Wilfred12

Affiliation:

1. Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, MD 21201, USA

2. Department of Physics, Medical Physics, University of Massachusetts Lowell, Lowell, MA 01854, USA

3. Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA

4. Department of Cell and Molecular Biology, Northeastern University, Boston, MA 02115, USA

5. Department of Radiation Oncology, Weill Cornell Medicine, New York, NY 10065, USA

6. NanoCan Therapeutics Corporation, Princeton, NJ 08540, USA

7. Department of Radiation Oncology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA

Abstract

Recent studies have highlighted the potential of smart radiotherapy biomaterials (SRBs) for combining radiotherapy and immunotherapy. These SRBs include smart fiducial markers and smart nanoparticles made with high atomic number materials that can provide requisite image contrast during radiotherapy, increase tumor immunogenicity, and provide sustained local delivery of immunotherapy. Here, we review the state-of-the-art in this area of research, the challenges and opportunities, with a focus on in situ vaccination to expand the role of radiotherapy in the treatment of both local and metastatic disease. A roadmap for clinical translation is outlined with a focus on specific cancers where such an approach is readily translatable or will have the highest impact. The potential of FLASH radiotherapy to synergize with SRBs is discussed including prospects for using SRBs in place of currently used inert radiotherapy biomaterials such as fiducial markers, or spacers. While the bulk of this review focuses on the last decade, in some cases, relevant foundational work extends as far back as the last two and half decades.

Funder

National Institutes of Health

Company NanoCan Therapeutics Corporation

Publisher

MDPI AG

Subject

General Materials Science,General Chemical Engineering

Reference87 articles.

1. The American Cancer Society Medical and Editorial Content Team (2022, May 28). Chemotherapy for Pancreatic Cancer. Available online: https://www.cancer.org/cancer/pancreatic-cancer/treating/chemotherapy.html.

2. Critically short telomeres and toxicity of chemotherapy in early breast cancer;Soberon;Oncotarget,2017

3. Engineering patient-specific cancer immunotherapies;Scheetz;Nat. Biomed. Eng.,2019

4. Antitumor immune responses induced by ionizing irradiation and further immune stimulation;Frey;Cancer Immunol. Immunother.,2014

5. Using immunotherapy to boost the abscopal effect;Ngwa;Nat. Rev. Cancer,2018

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3